Data from drug-resistant chronic myeloid leukemia patients demonstrate that treatment with a small-molecule inhibitor generates resistance via mutation or amplification of BCR-ABL. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.